The ligand-independent activation of FGFR2 is a known oncogenic event [17] predominantly found in intrahepatic cholangiocarcinoma with a prevalence of around 13% [11, 18]. This evidence concerns the gene FGFR2 and intrahepatic cholangiocarcinoma.